Kura Oncology (KURA) director receives grant of 35,000 stock options at $8.77

Rhea-AI Filing Summary

Kura Oncology director Michael Vasconcelles received a new stock option grant covering 35,000 shares of common stock. The option has an exercise price of $8.77 per share and was granted at no upfront cost. It vests in full on the one-year anniversary of the grant date and expires on June 3, 2036. Following this award, Vasconcelles holds options for 35,000 shares directly, reflecting a compensation-related grant rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider VASCONCELLES MICHAEL

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	35,000	$0.00	--

Holdings After Transaction: Option to purchase common stock — 35,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 35,000 shares Exercise price: $8.77 per share Post-grant option holdings: 35,000 shares +1 more

4 metrics

Option grant size 35,000 shares Options to purchase common stock granted to director

Exercise price $8.77 per share Exercise price of granted options

Post-grant option holdings 35,000 shares Total shares underlying options after transaction

Expiration date June 3, 2036 Option expiration for 35,000-share grant

Key Terms

Option to purchase common stock, exercise price, expiration date, Grant, award, or other acquisition, +1 more

5 terms

Option to purchase common stock financial

"security_title: Option to purchase common stock"

exercise price financial

"conversion_or_exercise_price: 8.7700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vests in full financial

"This option vests in full on the one year anniversary"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VASCONCELLES MICHAEL

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$8.77	06/04/2026		A		35,000		(1)	06/03/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. This option vests in full on the one year anniversary of the date of grant.

	/s/ Teresa Bair, Attorney-in-fact for Michael Vasconcelles	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Kura Oncology (KURA) disclose in this Form 4?

Kura Oncology reported that director Michael Vasconcelles received a grant of stock options for 35,000 shares of common stock. The award is a compensation-related grant, not an open-market stock purchase or sale, and is documented as a derivative transaction on the Form 4.

How many Kura Oncology (KURA) shares are covered by the new option grant?

The new option grant to director Michael Vasconcelles covers 35,000 shares of Kura Oncology common stock. After this grant, he holds options for the same 35,000 underlying shares directly, according to the reported post-transaction holdings on the Form 4 filing.

What is the exercise price of Michael Vasconcelles’ Kura Oncology (KURA) stock options?

The granted options have an exercise price of $8.77 per share for Kura Oncology common stock. This price is the amount payable per share if the options are exercised, as specified in the derivative transaction details of the Form 4 filing.

When do the newly granted Kura Oncology (KURA) options vest for Michael Vasconcelles?

The option grant vests in full on the one-year anniversary of the grant date. A footnote to the Form 4 states that the entire 35,000-share option becomes exercisable at that time, rather than vesting in multiple installments over several years.

When do Michael Vasconcelles’ Kura Oncology (KURA) stock options expire?

The reported stock options expire on June 3, 2036, giving a long-dated exercise window. This expiration date applies to the entire 35,000-share option grant and is specified in the derivative security details included in the Form 4 transaction table.

Was the Kura Oncology (KURA) Form 4 transaction an open-market buy or sell?

The Form 4 shows a grant or award acquisition of derivative securities, not an open-market trade. The transaction code is "A," indicating a compensation-related option grant to director Michael Vasconceles, with no reported open-market buying or selling of common shares.